---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Place in treatment, anticipated use, and care setting. Topics: Summary: anticipated place in therapy; Target population of the pivotal AMPLITUDE trial; Manufacturer estimates of the AMKD population, including people with comorbidities; Populations evaluated beyond the pivotal trial: AMPLIFIED; 6 further topics. 10 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: anticipated place in therapy

Inaxaplin is investigational, and no labeled indication exists. The pivotal AMPLITUDE trial enrolls participants aged 10 to 65 years with two APOL1 variants (G1/G1, G2/G2, or G1/G2), a urine protein to creatinine ratio (UPCR) of 0.7 to less than 10 g/g, and an eGFR of 25 to less than 75 mL/min/1.73 m2, and excludes people with diabetes mellitus, a solid organ or bone marrow transplant, or another known cause of kidney disease. Inaxaplin is given as 45 mg once daily on top of standard of care. Vertex states that a positive AMPLITUDE interim analysis could form the basis for potential U.S. accelerated approval, and Vertex investor relations stated that AMPLITUDE could unlock a population of about 150,000 people in the U.S. and Europe. Vertex estimates approximately 100,000 further people with AMKD and comorbidities such as type 2 diabetes. The phase 2 AMPLIFIED study dosed 41 participants with modest proteinuria (cohort 1, n=23) or with type 2 diabetes (cohort 2, n=18), populations Vertex describes as not being studied in AMPLITUDE, and Fierce Biotech reported that an FDA label covering both cohorts would add about 100,000 people to the target population.

Use would depend on APOL1 genotyping. A Vertex-sponsored test describes a genetic test for two APOL1 risk variants as required for a definitive diagnosis of AMKD; trial eligibility used a Vertex-designated investigational assay, and the Vertex-sponsored Labcorp test states that it has not been cleared or approved by the FDA. A Delphi consensus panel agreed that nephrologists should counsel patients about APOL1 high-risk genotypes, order the test, and return results, and that if a treatment becomes available all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with counseling. The KDIGO Controversies Conference report states that when treatments become available, “patient access to nephrologists with experience or knowledge of APOL1 kidney disease will be paramount”. In a U.S. real-world cohort of 1,332 people with AMKD, 45.7% had CKD stage 4 or 5 at a mean age of 45.6 years, 35.7% had at least one administration or fill of a RAAS inhibitor, and 10.5% of an SGLT2 inhibitor.

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in); [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm); [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity); [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996); [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping); [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/); [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/); [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="topic-2.2.2.2-2"></a>

### Target population of the pivotal AMPLITUDE trial

> “Our Ph2/3, randomized, double-blind, placebo-controlled, adaptive trial is enrolling persons (Ph2:18-65yrs; Ph3:10-65yrs) with 2 APOL1 variants, UPCR≥0.7 to <10g/g, and eGFR≥25 to <75mL/min/1.73m2.”
> “Our Ph2/3 trial will evaluate the effects of IXP on preserving kidney function and reducing proteinuria in a broad AMKD population.”

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

> “APOL1 genotype of G1/G1, G2/G2, or G1/G2”
> “Solid organ or bone marrow transplant”
> “Uncontrolled hypertension”
> “History of diabetes mellitus”
> “Known underlying cause of kidney disease including but not limited to sickle cell disease”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.2.2.2-3"></a>

### Manufacturer estimates of the AMKD population, including people with comorbidities

> “AMKD occurs in people with African ancestry, with an estimated patient population of approximately 150,000 people in the U.S. and Europe.”
> “In addition, we estimate that there are approximately 100,000 people with AMKD with comorbidities, such as type 2 diabetes, in the U.S. and Europe”
> “Our serial innovation strategy in AMKD focuses on indication expansion: evaluating inaxaplin in new populations of people with AMKD not included in the AMPLITUDE clinical trial.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”
> “If positive, the data could form the basis for potential accelerated approval in the U.S.”
> “AMKD affects approximately 150,000 people in the U.S. and Europe. There are no therapies currently approved for AMKD.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.2.2-4"></a>

### Populations evaluated beyond the pivotal trial: AMPLIFIED

> “Forty-one people were enrolled and dosed in two cohorts: 1) people with AMKD with modest proteinuria (UACR ≥0.1 g/g to <0.42 g/g) were eligible for cohort 1 (N=23), and 2) people with AMKD, type 2 diabetes and proteinuria (UACR ≥0.1 g/g to <6 g/g) were eligible for cohort 2 (N=18).”
> “AMPLIFIED is a Phase 2, single-arm, open-label study evaluating the effect of treatment with a 45 mg once-daily dose of inaxaplin for 13 weeks to reduce proteinuria in people with AMKD with modest proteinuria, and people with AMKD and type 2 diabetes”
> “populations not being studied in the AMPLITUDE trial.”
> “We look forward to discussing the AMPLIFIED results with regulators in the context of the AMPLITUDE pivotal study.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “Given the potential of IXP to treat AMKD, it is essential to assess its efficacy in a broader population, including many of whom have comorbidities that may independently contribute to chronic kidney disease and accelerate disease progression.”
> “AMPLIFIED is a phase 2, open-label study evaluating the efficacy of IXP to reduce proteinuria in 45 participants (ages 18-67yrs) with proteinuric AMKD who have none (Cohort 1,n=15) or one of the following significant comorbidities: type 2 diabetes mellitus (Cohort 2,n=15), sickle-cell disease (Cohort 3,n=5), human immunodeficiency virus (Cohort 3,n=5), or lupus nephritis (Cohort 3,n=5).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-2.2.2.2-5"></a>

### Size of the target population by scope of a future label

> “Amplitude could unlock a population with about 150,000 patients in the U.S. and Europe, Susie Lisa, senior vice president of investor relations at Vertex, said at a Wells Fargo event this week.”
> “An FDA label covering the two arms in Amplified would add about 100,000 patients to the target population.”

Source: [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)

<a id="topic-2.2.2.2-6"></a>

### Use in addition to standard of care

> “Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care.”
> “In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care.”
> “These patients were already well treated with foundational chronic kidney disease therapies and treatment with inaxaplin led to additional reductions in proteinuria.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.2.2.2-7"></a>

### APOL1 genotyping as the gatekeeper to diagnosis and eligibility

> “A definitive diagnosis of AMKD requires a genetic test for the presence of two APOL1 risk variants”
> “This test is sponsored by Vertex and should only be ordered on eligible patients. Eligible patients include those of African ancestry who may self-identify as Black, African American, African or Afro-Caribbean, a diagnosis of chronic kidney disease, no history of kidney transplant, do not have diabetes and must not be currently treated with dialysis.”
> “This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

> “Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

> “The high prevalence of 2 APOL1 variants in participants with recent African ancestry and proteinuric CKD reinforces the importance of APOL1 genotyping to optimize kidney disease management and enable referral to clinical trials of APOL1-targeted therapies.”

Source: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

<a id="topic-2.2.2.2-8"></a>

### Expert consensus on testing and treatment initiation once a treatment is available

> “If a treatment for APOL1-associated nephropathy becomes available, all patients suspected of having APOL1-associated nephropathy should be offered genetic testing with appropriate counseling”
> “If a treatment for APOL1-associated nephropathy becomes available, all Black people (or those with sub-Saharan African ancestry) with CKD should be offered genetic testing with appropriate counseling”
> “If a treatment for APOL1-associated nephropathy becomes available, intervention should begin as early as possible in patients with APOL1-associated nephropathy on the basis of data from clinical trials”
> “If a treatment for APOL1-associated nephropathy was available, a kidney biopsy should be performed to confirm the diagnosis in individuals with high-risk APOL1 genotypes”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.2-9"></a>

### Care setting: nephrology

> “Nephrologists should be responsible for counseling patients in their practice about the APOL1 high-risk genotypes as appropriate, ordering the APOL1 test, and returning results to patients”
> “APOL1 testing is not common in routine clinical practice; it is carried out in only a few specialist centers, often as part of APOL1 research”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

> “When treatments become available, patient access to nephrologists with experience or knowledge of APOL1 kidney disease will be paramount, as will affordability of any new therapies.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.2.2-10"></a>

### Current treatment and disease stage among people with AMKD

> “Patients with evidence of diabetes, autosomal dominant polycystic kidney disease, or IgA nephropathy were excluded, leaving 1332 patients with a mean (SD) age of 45.6 (15.4) years.”
> “Hypertension (88.9%), hyperlipidemia (42.3%), and chronic pulmonary disease (23.1%) were the most common comorbidities, and 45.7% of patients were in CKD stage 4 or 5.”
> “Within the study period, 35.7% of patients had at least 1 administration or fill of a RAAS inhibitor, 35% of a calcium channel blocker, 27.9% of a beta blocker, 10.5% of an SGLT2 inhibitor, and 4.4% of a GLP-1 receptor agonist.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
